[Effectiveness of a protocol treatment for overweight/obese patients (SIAN - ASL RMA)]. / Efficacia di un protocollo di trattamento per i pazienti in sovrappeso/obesi negli Ambulatori di Dietetica Preventiva del SIAN RMA.

OBJECTIVES: To evaluate the efficacy of treatment protocols in patients overweight/obese, pertaining to outpatient of dietary preventive of SIAN (in English: Service of Food Hygiene and Nutrition) RMA. MATERIALS AND METHODS: We extracted data from the medical records of patients with BMI≥25 (2009-2012). It was conducted a descriptive analysis, univariate analysis (chi-square test; p≤0.05) and multivariate logistic regression analysis considering as "weight loss" the outcome measure. RESULTS: There were 762 records (76.2% female; mean age 52 years). BMI average of beginning treatment: 30.26; BMI of the end of treatment: 28.37; minimum maximum range of variation of weight after treatment: -28.9 Kg and +6.5 Kg. The 55.2% of the sample has lost up to 4.9 kg, 32.4% from 5.0 to 9.9 kg, 8.1% from 10.0 to 19.9 Kg, 0.9% from 20 to 28.9 Kg. The higher initial BMI and the longer treatment, have a lower likelihood of weight loss (B=-1.267, p<0.001; B =-0.408, p<0.001); females and those who have an older age are more likely to lose weight (B=0.030, p<0.003; B=1.260, p<0.001). CONCLUSIONS: The current study highlight the efficacy of treatment protocols in overweight/obese patients. The population that benefits from the treatment more rigidly set on the estimated caloric needs is the one that starts from lower BMI and who therefore need less time to reach a certain weight loss. Instead, those who started from higher BMI is a population supposedly "binger", more resistant to the single dietary treatment and, as recognized by the scientific community, it requires a multidisciplinary approach.

[Simvastatin in the treatment of hypercholesterolemia]. / La simvastatina nel trattamento delle ipercolesterolemie.

We have treated twelve patients with simvastatin: six had type IIA hypercholesterolaemia and the other six had type IIB. These patients have been examined before and after therapy, by an ophthalmologist. After therapy, the levels of the total cholesterol and triglycerides were decreased while HDL cholesterol was increased. Untoward side effects of ophthalmologic alterations were not observed.

[Hyperlipidemia: physiopathology and our experience in the ambulatory care of 3 groups of patients undergoing blood lipid normalization treatment]. / Le iperlipidemie. Fisiopatologia e nostre esperienze ambulatoriali su tre gruppi di pazienti sottoposti a trattamento normolipemizzante.

The authors tested the efficacy of three different lipid-lowering drugs in subjects with more or less severe alterations of the lipoprotein pattern. All subjects were submitted to blood tests prior to and at the end of treatment with special attention to the trend of the lipid pattern, assaying cholesterol, HDL, LDL, triglyceride, total lipid blood levels and lipid electrophoresis. The drugs employed were: pantothenic acid, sulodexide, and DEAE-dextran.

[Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches]. / Colite ulcerosa criptogenetica. Nostra esperienza clinica sulle nuove vedute terapeutiche.

Sixteen patients with flare-ups of ulcerative colitis were studied. Before and after treatment, patients were submitted to the customary laboratory tests and to x-ray (contrast enema) and endoscopic examination, biopsy material being harvested during the latter. Treatment consisted in the oral administration of 2-4 g 5-ASA daily for 30 days. Only one patient did not tolerate 5-ASA which was withdrawn. All other patients had good or very good results with remission of symptoms.